Hasil Pencarian - Noriyuki Ebi

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)

    A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK... oleh Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Masafumi Takeshita, Takayuki Suetsugu, Keisuke Kirita, Noriyuki Ebi, Osamu Hataji, Satoru Miura, Kenji Chibana, Isamu Okamoto, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto, Kenji Sugio

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)

    Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L) oleh Ryoji Kato, Hidetoshi Hayashi, Eriko Miyawaki, Junichi Shimizu, Tomohiro Ozaki, Daichi Fujimoto, Ryo Toyozawa, Atsushi Nakamura, Toshiyuki Kozuki, Kentaro Tanaka, Shunsuke Teraoka, Kazuhiro Usui, Kazumi Nishino, Osamu Hataji, Keiichi Ota, Noriyuki Ebi, Sho Saeki, Yuki Akazawa, Motoyasu Okuno, Kazuhiko Nakagawa

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study

    Survival Impact of Second-Line Immune Checkpoint Inhibitors in Older Patients With Advanced Squamous-Cell NSCLC: Post Hoc Analysis of the CAPITAL Study oleh Yoshihito Kogure, MD, PhD, Akiko Kada, MPH, Hiroya Hashimoto, PhD, Shinji Atagi, MD, Yuichi Takiguchi, MD, Hideo Saka, MD, Noriyuki Ebi, MD, Akira Inoue, MD, Takayasu Kurata, MD, Yuka Fujita, MD, Yoichi Nishii, MD, Hidetoshi Itani, MD, Takeo Endo, MD, Akiko M. Saito, MD, Takuo Shibayama, MD, Nobuyuki Yamamoto, MD, Akihiko Gemma, MD

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment

    The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment oleh Naoko Sueoka‐Aragane, Chiho Nakashima, Hironori Yoshida, Naohisa Matsumoto, Kentaro Iwanaga, Noriyuki Ebi, Akihiro Nishiyama, Kazuhiro Yatera, Shoichi Kuyama, Minoru Fukuda, Sunao Ushijima, Hitomi Umeguchi, Daijiro Harada, Kosuke Kashiwabara, Takayuki Suetsugu, Nobukazu Fujimoto, Fumihiro Tanaka, Hidetaka Uramoto, Chiharu Yoshii, Katsumi Nakatomi, Genju Koh, Nobuhiko Seki, Keisuke Aoe, Kaname Nosaki, Koji Inoue, Ayako Takamori, Atsushi Kawaguchi

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060

    Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060 oleh Takehiro Tozuka, MD, Yuji Minegishi, MD, PhD, Ou Yamaguchi, MD, PhD, Kana Watanabe, MD, Yukihiro Toi, MD, Ryota Saito, MD, PhD, Yoshiaki Nagai, MD, PhD, Yosuke Tamura, MD, PhD, Tetsuaki Shoji, MD, PhD, Haruka Odagiri, MD, Noriyuki Ebi, MD, Kosuke Sakai, MD, PhD, Nobuhiro Kanaji, MD, PhD, Makoto Izumi, MD, Sayo Soda, MD, PhD, Satoshi Watanabe, MD, PhD, Satoshi Morita, PhD, Kunihiko Kobayashi, MD, PhD, Masahiro Seike, MD, PhD

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

    Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations oleh Kiichiro Ninomiya, MD, PhD, Shunsuke Teraoka, MD, Yoshitaka Zenke, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Yukiko Nakamura, MD, Yusuke Okuma, MD, PhD, Akihiro Tamiya, MD, Kaname Nosaki, MD, Masahiro Morise, MD, PhD, Keiju Aokage, MD, Yuko Oya, MD, Toshiyuki Kozuki, MD, PhD, Tomohiro Sakamoto, MD, PhD, Kentaro Tanaka, MD, PhD, Hisashi Tanaka, MD, PhD, Junko Tanizaki, MD, PhD, Satoru Miura, MD, PhD, Hideaki Mizutani, MD, Eisaku Miyauchi, MD, PhD, Ou Yamaguchi, MD, PhD, Noriyuki Ebi, MD, Yasushi Goto, MD, PhD, Takaaki Sasaki, MD, PhD, Haruko Daga, MD, PhD, Satoshi Morita, PhD, Takeharu Yamanaka, PhD, Shinsuke Amano, BCom, Kazuo Hasegawa, BFA, Chiyo K. Imamura, PhD, Kenichi Suzuki, PhD, Kazuko Nakajima, PhD, Hitomi Nishimoto, MN, Satoshi Oizumi, MD, PhD, Toyoaki Hida, MD, PhD, Katsuyuki Hotta, MD, PHD, MPH, Yuichi Takiguchi, MD, PhD

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: